AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+9.46%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$3.03B
AUM Growth
+$3.03B
(+3.1%)
Cap. Flow
+$76.1M
Cap. Flow
% of AUM
2.51%
Top 10 Holdings %
Top 10 Hldgs %
46.17%
Holding
153
New
22
Increased
19
Reduced
69
Closed
16
Top Buys
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$83M |
| 2 |
KLRS
Kalaris Therapeutics, Inc. Common Stock
KLRS
|
$63.9M |
| 3 |
KE Holdings
BEKE
|
$53.3M |
| 4 |
IGMS
IGM Biosciences
IGMS
|
$50.8M |
| 5 |
iTeos Therapeutics
ITOS
|
$27M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$42.9M |
| 2 |
PayPal
PYPL
|
$34.8M |
| 3 |
Avantor
AVTR
|
$34M |
| 4 |
argenx
ARGX
|
$33M |
| 5 |
Zillow
Z
|
$28.7M |
Sector Composition
| 1 | Healthcare | 78.37% |
| 2 | Consumer Discretionary | 13.95% |
| 3 | Technology | 3.4% |
| 4 | Real Estate | 1.76% |
| 5 | Materials | 1.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Aurinia Pharmaceuticals
AUPH
$1.58B
| $14.7M | 0.36% | 1,000,000 +100,000 | +11% | +$1.47M |
|
52
Ovid Therapeutics
OVID
$91M
| $14.4M | 0.35% | +2,500,000 | New | +$14.4M |
|
53
Denali Therapeutics
DNLI
$2.23B
| $14.3M | 0.35% | 400,000 -50,000 | -11% | -$1.79M |
|
|
HARP
54
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $13.6M | 0.33% | 800,000 -100,000 | -11% | -$1.7M |
|
|
SAGE
55
DELISTED
Sage Therapeutics
SAGE
| $13.6M | 0.33% | 222,300 -11,700 | -5% | -$715K |
|
|
SWTX
56
DELISTED
SpringWorks Therapeutics
SWTX
| $13.6M | 0.33% | 285,000 -15,000 | -5% | -$715K |
|
|
MTCR
57
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $13.4M | 0.32% | +1,309,513 | New | +$13.4M |
|
58
Iovance Biotherapeutics
IOVA
$807M
| $13.2M | 0.32% | 400,000 -100,000 | -20% | -$3.29M |
|
59
Cardiff Oncology
CRDF
$140M
| $12.8M | 0.31% | +900,000 | New | +$12.8M |
|
|
EPZM
60
DELISTED
Epizyme, Inc
EPZM
| $11.9M | 0.29% | 1,000,000 -875,000 | -47% | -$10.4M |
|
61
Cartesian Therapeutics
RNAC
$261M
| $11.2M | 0.27% | 4,500,000 +1,600,000 | +55% | +$3.97M |
|
62
Cyclerion Therapeutics
CYCN
$7.91M
| $11.1M | 0.27% | 1,817,584 -24,000 | -1% | -$146K |
|
63
Y-mAbs Therapeutics
YMAB
$388M
| $10.9M | 0.27% | 285,028 -15,002 | -5% | -$576K |
|
64
Royalty Pharma
RPRX
$15.6B
| $10.5M | 0.26% | 250,000 -500,000 | -67% | -$21M |
|
65
Krystal Biotech
KRYS
$4.27B
| $10.2M | 0.25% | 237,500 +37,500 | +19% | +$1.61M |
|
|
TCRR
66
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $10.2M | 0.25% | 500,000 +150,000 | +43% | +$3.05M |
|
67
Esperion Therapeutics
ESPR
$448M
| $9.29M | 0.23% | +250,000 | New | +$9.29M |
|
68
Stoke Therapeutics
STOK
$1.08B
| $9.07M | 0.22% | 270,750 -14,250 | -5% | -$477K |
|
69
Seres Therapeutics
MCRB
$166M
| $8.49M | 0.21% | +300,000 | New | +$8.49M |
|
70
Kymera Therapeutics
KYMR
$2.95B
| $8.08M | 0.2% | +250,000 | New | +$8.08M |
|
71
Applied Therapeutics
APLT
$71M
| $7.89M | 0.19% | +380,000 | New | +$7.89M |
|
72
Dyne Therapeutics
DYN
$1.92B
| $7.47M | 0.18% | +370,000 | New | +$7.47M |
|
73
Spyre Therapeutics
SYRE
$996M
| $7.41M | 0.18% | 1,045,000 -55,000 | -5% | -$390K |
|
74
PMV Pharmaceuticals
PMVP
$74.2M
| $7.1M | 0.17% | +200,000 | New | +$7.1M |
|
75
Bruker
BRKR
$5.16B
| $6.97M | 0.17% | 175,275 -9,225 | -5% | -$367K |
|